Project Name: การศึกษาความสัมพันธ์ระหว่างระดับ urocortin ในเลือดกับการทำงานของหัวใจล่างด้านซ้ายของผู้ป่วยที่มีภาวะกล้ามเนื้อหัวใจ ตายเฉียบพลัน (Relation of plasma urocortins and left ventricular function in acute myocardial infarction patients.)

Researcher: Nipon Chattipakorn


Time:1 October 2006 - 30 September 2007


  1. Nipon Chattipakorn (Head of project)
  2. Narissara Lailerd (Corporate person of project)


  1. BioMedical Engineering Center 324,180 Baht


Myocardial infarction is a common presentation of ischemic heart disease. The WHO estimated that in 2002, 12.6% of deaths worldwide were from ischemic heart disease. Ischemic heart disease is the leading cause of death in developed countries as well as in Thailand. Since, the adverse progress following myocardial infarction can lead to left ventricular dysfunction; including systolic and diastolic dysfunction, heart failure and sudden cardiac death.  Therefore, current medical treatment focuses on the prevention of the progression of diseases.  In the past decades, several cardiac markers have been shown a predictive value regarding the progression and the prognosis of myocardial infarction and heart failure patients.  These markers include NT-proBNP, Cardiac troponin, hs-CRP, and Creatine kinase.  However, these cardiac markers alone were often unsatisfactory because these cardiac markers may affect via other pathophysiological conditions including inflammation or other diseases.  Recently, a novel cardiovascular peptide, "Urocortins", has been emphasized its potential value as an early diagnostic marker in ventricular dysfunction and heart failure. To date, most work has been performed on urocortins in relation to cardioprotection against ischemia and reperfusion injury in animal studies. Urocortins not only increases cardiac contractility and is a vasodilator but also prevents necrosis and apoptosis following stimulated hypoxia/ischemia. 
These cardiovascular effects of urocortins prompted us to investigate its plasma levels in human with acute myocardial infarction, firstly to understand whether urocortins has a role in the pathophysiology of myocardial infarction, and secondly, to assess its value as a diagnostic tool for adverse progressive following acute myocardial infarction.